Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats.
10.4093/dmj.2012.36.2.128
- Author:
Jae Hee AHN
1
;
Ho Cheol HONG
;
Myong Jin CHO
;
Yoon Jung KIM
;
Hae Yoon CHOI
;
Chai Ryoung EUN
;
Sae Jeong YANG
;
Hye Jin YOO
;
Hee Young KIM
;
Ji A SEO
;
Sin Gon KIM
;
Kyung Mook CHOI
;
Sei Hyun BAIK
;
Dong Seop CHOI
;
Nan Hee KIM
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. nhkendo@gmail.com
- Publication Type:Original Article
- Keywords:
Aldosterone receptor blocker;
Diabetic nephropathy;
Eplerenone;
Lisinopril;
Type 2 diabetic rats
- MeSH:
Aldosterone;
Animals;
Collagen Type IV;
Connective Tissue Growth Factor;
Diabetic Nephropathies;
Fibronectins;
Lisinopril;
Mineralocorticoid Receptor Antagonists;
Peptidyl-Dipeptidase A;
Plasminogen Activators;
Rats;
Rats, Inbred OLETF;
Receptors, Mineralocorticoid;
Renin-Angiotensin System;
RNA, Messenger;
Spironolactone
- From:Diabetes & Metabolism Journal
2012;36(2):128-135
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Aldosterone antagonists are reported to have beneficial effects on diabetic nephropathy by effective blocking of the renin-angiotensin-aldosterone system. We investigated the renoprotective effect of the selective aldosterone receptor blocker eplerenone, the angiotensin converting enzyme inhibitor lisinopril, and combined eplerenone and lisinopril treatment in type 2 diabetic rats. METHODS: Animals were divided into six groups as follows: Otsuka Long-Evans Tokushima Fatty (OLETF) rat control, OLETF rats treated with a low dose of eplerenone (50 mg/kg/day), OLETF rats treated with a high dose of eplerenone (200 mg/kg/day), OLETF rats treated with lisinopril (10 mg/kg/day), OLETF rats treated with a combination of both drugs (eplerenone 200 mg/kg/day and lisinopril 10 mg/kg/day), and obese non-diabetic Long-Evans Tokushima Otsuka rats for 26 weeks. RESULTS: Urinary albumin excretion was significantly lower in the lisinopril group, but not in the eplerenone group. Urinary albumin excretion was decreased in the combination group than in the lisinopril group. Glomerulosclerosis and renal expression of type I and type IV collagen, plasminogen activator inhibitor-1, transforming growth factor-beta1, connective tissue growth factor, and fibronectin mRNA were markedly decreased in the lisinopril, eplerenone, and combination groups. CONCLUSION: Eplerenone and lisinopril combination showed additional benefits on type 2 diabetic nephropathy compared to monotherapy of each drug.
